BR9205700A - Aperfeiçoamento em um processo para purificar e preservar fator IX derivado de plasma do sangue humano ou outra fonte, processos para a preparação de uma composição terapêutica, e para estabilizar fator IX, solução aquosa de fator IX parcialmente purificado, composição terapêutica e processo para tratar doença de christmas. - Google Patents

Aperfeiçoamento em um processo para purificar e preservar fator IX derivado de plasma do sangue humano ou outra fonte, processos para a preparação de uma composição terapêutica, e para estabilizar fator IX, solução aquosa de fator IX parcialmente purificado, composição terapêutica e processo para tratar doença de christmas.

Info

Publication number
BR9205700A
BR9205700A BR9205700A BR9205700A BR9205700A BR 9205700 A BR9205700 A BR 9205700A BR 9205700 A BR9205700 A BR 9205700A BR 9205700 A BR9205700 A BR 9205700A BR 9205700 A BR9205700 A BR 9205700A
Authority
BR
Brazil
Prior art keywords
factor
therapeutic composition
derived
blood plasma
stabilize
Prior art date
Application number
BR9205700A
Other languages
English (en)
Inventor
Chin C Huang
Takashi Enkoji
Laura Ho
Richard R Kleszynski
Richard L Weeks
Fred Feldman
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Publication of BR9205700A publication Critical patent/BR9205700A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
BR9205700A 1991-03-01 1992-02-26 Aperfeiçoamento em um processo para purificar e preservar fator IX derivado de plasma do sangue humano ou outra fonte, processos para a preparação de uma composição terapêutica, e para estabilizar fator IX, solução aquosa de fator IX parcialmente purificado, composição terapêutica e processo para tratar doença de christmas. BR9205700A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292791A 1991-03-01 1991-03-01
PCT/US1992/001600 WO1992015324A1 (en) 1991-03-01 1992-02-26 Preparation of factor ix

Publications (1)

Publication Number Publication Date
BR9205700A true BR9205700A (pt) 1994-06-28

Family

ID=24659784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9205700A BR9205700A (pt) 1991-03-01 1992-02-26 Aperfeiçoamento em um processo para purificar e preservar fator IX derivado de plasma do sangue humano ou outra fonte, processos para a preparação de uma composição terapêutica, e para estabilizar fator IX, solução aquosa de fator IX parcialmente purificado, composição terapêutica e processo para tratar doença de christmas.

Country Status (17)

Country Link
US (3) US6063909A (pt)
EP (1) EP0573605B1 (pt)
JP (1) JP3418621B2 (pt)
AT (1) ATE195877T1 (pt)
AU (1) AU671586B2 (pt)
BR (1) BR9205700A (pt)
CA (1) CA2105282C (pt)
DE (1) DE69231401T2 (pt)
DK (1) DK0573605T3 (pt)
ES (1) ES2150914T3 (pt)
FI (1) FI114969B (pt)
GR (1) GR3034946T3 (pt)
MX (1) MX9200882A (pt)
NO (1) NO315856B1 (pt)
RU (1) RU2142806C1 (pt)
SG (1) SG48282A1 (pt)
WO (1) WO1992015324A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0573605T3 (da) * 1991-03-01 2001-01-02 Rhone Poulenc Rorer Int Fremstilling af faktor IX
WO1994005692A1 (en) * 1992-08-27 1994-03-17 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DE19506633A1 (de) 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
WO1998018957A1 (de) * 1996-10-31 1998-05-07 Roche Diagnostics Gmbh VERFAHREN ZUR BESTIMMUNG DER KATALYTISCHEN AKTIVITÄT VON FAKTOR IXa
WO2002040544A2 (en) * 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
MXPA05010846A (es) * 2003-04-09 2006-03-30 Nektar Therapeutics Tratamiento de hemofilia mediante inhalacion de factores de coagulacion.
US8158139B2 (en) * 2004-07-12 2012-04-17 Taro Pharmaceuticals North America, Inc. Topical gel formulation comprising organophosphate insecticide and preparation thereof
US8012498B2 (en) 2004-07-12 2011-09-06 Sandhya Goyal Topical gel formulation comprising organophosphate insecticide and preparation thereof
US7560445B2 (en) * 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
US9896677B2 (en) 2010-01-18 2018-02-20 Novo Nordisk Health Care Ag Purification of blood coagulation factors
DK3133157T3 (da) * 2010-03-30 2019-08-12 Octapharma Ag Fremgangsmåde til oprensning af vitamin k-afhængige proteiner
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
EP0118256B1 (en) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbent, and method of recovering vitamin-k dependent protein therewith
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
ATE36457T1 (de) * 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
JPS60132912A (ja) * 1983-12-21 1985-07-16 Kao Corp シヤンプ−組成物
DE3684546D1 (de) * 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
FR2600334B1 (fr) 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
ES2045167T5 (es) 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
JPH01258700A (ja) 1988-04-05 1989-10-16 Green Cross Corp:The 血液凝固第４因子の精製方法
DE3826792C1 (pt) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3914869C1 (pt) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
DK0573605T3 (da) * 1991-03-01 2001-01-02 Rhone Poulenc Rorer Int Fremstilling af faktor IX

Also Published As

Publication number Publication date
WO1992015324A1 (en) 1992-09-17
ATE195877T1 (de) 2000-09-15
DK0573605T3 (da) 2001-01-02
EP0573605A1 (en) 1993-12-15
SG48282A1 (en) 1998-04-17
US6043215A (en) 2000-03-28
FI933814A (fi) 1993-09-01
RU2142806C1 (ru) 1999-12-20
AU1642992A (en) 1992-10-06
DE69231401T2 (de) 2001-02-08
AU671586B2 (en) 1996-09-05
US6063909A (en) 2000-05-16
FI933814A0 (fi) 1993-09-01
CA2105282A1 (en) 1992-09-02
JPH06505494A (ja) 1994-06-23
GR3034946T3 (en) 2001-02-28
MX9200882A (es) 1992-09-01
NO315856B1 (no) 2003-11-03
CA2105282C (en) 2002-09-24
JP3418621B2 (ja) 2003-06-23
US6280729B1 (en) 2001-08-28
ES2150914T3 (es) 2000-12-16
EP0573605B1 (en) 2000-08-30
EP0573605A4 (en) 1994-11-23
DE69231401D1 (de) 2000-10-05
NO933114D0 (no) 1993-09-01
FI114969B (fi) 2005-02-15
NO933114L (no) 1993-09-01

Similar Documents

Publication Publication Date Title
BR9205700A (pt) Aperfeiçoamento em um processo para purificar e preservar fator IX derivado de plasma do sangue humano ou outra fonte, processos para a preparação de uma composição terapêutica, e para estabilizar fator IX, solução aquosa de fator IX parcialmente purificado, composição terapêutica e processo para tratar doença de christmas.
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE279930T1 (de) Wässerige alkalimetallbicarbonat-lösungen zur benahdlung von osteoarthrose
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
BR9916732A (pt) Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
ES2185646T3 (es) Soluciones de aminoacido mejoradas para el tratamiento de pacientes de dialisis peritoneal.
BR9710615A (pt) Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea.
AR002018A1 (es) Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y
RU93053992A (ru) Способ очистки и хранения фактора ix, водный раствор очищенного фактора ix, композиция, содержащая фактор ix, способ лечения
PT90356A (pt) Processo para a preparacao de composicoes farmaceuticas contendo solucoes aquosas de pentamidina
AR042019A1 (es) N-acetilgalactosamina-4-sulfatasa precursora, composiciones farmaceuticas que la contienen , metodos de tratamiento que la utilizan y metodos para producirla y purificarla
US6358918B1 (en) Preparation comprising thiol-group-containing proteins
ATE233562T1 (de) Verwendung von hyaluronsäure zur herstellung einer wässrigen lösung verwendbar als intra- artikulare reinigungslösung
ATE268380T1 (de) Thrombin zusammensetzung
HUP0002329A1 (hu) Peptidsók, előállításukra szolgáló eljárás és használatuk a gyógyításban
LU90993I2 (fr) Xigris-drotrécogine alfa(activée) et ses dérivés pharmaceutiquement acceptables
SE8703512D0 (sv) Medel for tandbehandling
BR0200291A (pt) Composição farmacêutica lìquida para o uso no tratamento de doenças ósseas, processo para preparar a mesma e processo para tratamento de uma doença óssea
ATE220319T1 (de) Ionische wässerige zusammensetzung enthaltend levomenthol
SE8506094D0 (sv) New antibacterial agents and intermediates therefor
BR0314187A (pt) Processo para produzir cristais do hormÈnio do crescimento
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี
RU93036929A (ru) Способ очистки препарата гадолиния-153 от европия-152
UA31714A (uk) Засіб для зовнішнього лікування гнійних ран і трофічних виразок

Legal Events

Date Code Title Description
HE Change of address
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal
B15K Others concerning applications: alteration of classification

Ipc: C12N 9/64 (2006.01), A61K 9/00 (2006.0